Business
Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
DUBLIN, Feb. 18, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery,
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"DUBLIN, Feb. 18, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations:\n\n \n \n\n \nSVB Leerink 9th Annual Global Healthcare Conference at 11:30 a.m. ET (8:30 a.m. PT/4:30 p.m. GMT) on Wednesday, February 26, 2020 Cowen and Company 40th Annual Health Care Conference at 1:30 p.m. ET (10:30 a.m. PT/6:30 p.m. GMT) on Monday, March 2, 2020Webcasts of the presentations may be accessed by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations and Events tab. Replays of the webcasts will be archived on the Company's website for at least 30 days.\nAbout Theravance Biopharma\nTheravance Biopharma, Inc. (\"Theravance Biopharma\") is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused in the areas of inflammation and immunology.\nIn pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant patient needs.\nWe have an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY ELLIPTA. \nFor more information, please visit www.theravance.com.\nTHERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma ...